These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31167998)

  • 1. [Acute myeloid leukemia evolving from KIT D816-mutated systemic mastocytosis relapsing two months after completion of chemotherapy].
    Harao T; Yamada A; Kinoshita M; Sawa D; Saito Y; Kamimura S; Miyachi H; Ogino T; Kodama Y; Okamoto Y; Kawano Y; Moritake H
    Rinsho Ketsueki; 2019; 60(5):378-381. PubMed ID: 31167998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
    Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
    Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Remission of Acute Myeloid Leukemia Developed From Systemic Mastocytosis by Conventional Chemotherapy.
    Yamada A; Kinoshita M; Sawa D; Saito Y; Kamimura S; Miyachi H; Moritake H
    J Pediatr Hematol Oncol; 2019 Aug; 41(6):e402-e404. PubMed ID: 30044348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia.
    Mahadeo KM; Wolgast L; McMahon C; Cole PD
    Pediatr Blood Cancer; 2011 Oct; 57(4):684-7. PubMed ID: 21671435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'.
    Rabade N; Tembhare P; Patkar N; Amare P; Arora B; Subramanian PG; Gujral S
    Indian J Pathol Microbiol; 2016; 59(3):407-9. PubMed ID: 27510692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
    Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
    Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).
    Johnson RC; Savage NM; Chiang T; Gotlib JR; Cherry AM; Arber DA; George TI
    Am J Clin Pathol; 2013 Oct; 140(4):525-35. PubMed ID: 24045550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22).
    Gadage VS; Kadam Amare PS; Galani KS; Mittal N
    Indian J Pathol Microbiol; 2012; 55(3):409-12. PubMed ID: 23032848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
    Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
    Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful outcome of allogeneic hematopoietic stem cell transplantation for systemic mastocytosis complicated with acute myeloid leukemia].
    Maegaki M; Kawamura K; Hara K; Suzuki S; Hosoda Y; Kuwamoto S; Motokura T; Fukuda T
    Rinsho Ketsueki; 2022; 63(1):14-19. PubMed ID: 35135946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review].
    Wang J; Zu YL; Gui RR; Li Z; Zhang Y; Zhou J
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):505-508. PubMed ID: 38964927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation.
    Bae MH; Kim HK; Park CJ; Seo EJ; Park SH; Cho YU; Jang S; Chi HS; Lee KH
    Ann Lab Med; 2013 Mar; 33(2):125-9. PubMed ID: 23483057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
    Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.